Barcelona, 7hMay 2013 Q1 Results on track to achieve yearly guidance Steady progr...
0.15* euros per share was approved as a flexible dividend; to be perceived in cash or ...
More Press releases Nuevo
- 02/05/2013 2013/05/02 2013/05/22 Almirall and Forest Laboratories announce positive results for the second Phase III study for aclidinium and formoterol combination in COPD
- 16/04/2013 2013/04/16 2013/05/22 Almirall and Forest Laboratories announce positive results of a Phase III Study for aclidinium and formoterol combination in COPD
- 01/03/2013 2013/03/01 2013/05/22 Almirall presents the latest news in respiratory diseases
- 19/02/2013 2013/02/19 2013/05/22 Coordination among professionals is crucial for good vascular patient care
- 08/02/2013 2013/02/08 2013/05/22 Almirall commercialises Neurofarmagen, an innovative genetic test